Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zaleplon
Drug ID BADD_D02379
Description Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Indications and Usage For the treatment of short-term treatment of insomnia in adults.
Marketing Status approved; illicit; investigational
ATC Code N05CF03
DrugBank ID DB00962
KEGG ID D00530
MeSH ID C085665
PubChem ID 5719
TTD Drug ID D09DWL
NDC Product Code 29300-131; 71335-1054; 71335-1387; 43063-783; 57237-239; 42043-210; 57237-240; 68788-7208; 53296-0056; 65862-215; 71335-0236; 0054-0085; 63629-3405; 65862-214; 16436-0056; 42043-211; 0054-0084; 71335-1466; 51846-1026; 65862-197; 29300-132; 43063-505; 43063-912; 45865-541; 64330-054
UNII S62U433RMH
Synonyms zaleplon | 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide | N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide | L 846 | L-846 | Zelepion | Starnoc | SKP-1041 | CL 284,846 | CL-284846 | CL284,846 | CL 284846 | Sonata
Chemical Information
Molecular Formula C17H15N5O
CAS Registry Number 151319-34-5
SMILES CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal pain20.02.03.003--Not Available
Retinal detachment12.01.04.004; 06.09.03.003--
Salivary hypersecretion07.06.01.009--Not Available
Shock24.06.02.002--Not Available
Sinus bradycardia02.03.03.009--
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin hypertrophy23.01.04.002--Not Available
Sleep talking19.02.03.005; 17.15.02.003--Not Available
Snoring22.12.03.025--Not Available
Somnambulism19.02.03.006; 17.15.02.004--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Sputum increased22.02.03.007--Not Available
Stomatitis07.05.06.005--
Stupor19.02.05.004; 17.02.04.007--Not Available
Swelling08.01.03.015--Not Available
Syncope24.06.02.012; 02.11.04.015; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tenosynovitis15.07.01.004--Not Available
Tension19.06.02.005--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.002--
Trismus15.05.04.004; 17.01.03.004--
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene